2018 4th International Smart Healthcare Innovation Forum and eHealthcare Innovation Awards Ceremony

Recently, UK Prime Minister Theresa May’s visit to China has rightly become a focal point of global attention. Wuhan, the city with the largest population of undergraduate and graduate students in the world, served as the first stop on her trip, where she led a large-scale business delegation described as having “almost emptied Britain.” Nearly 100 Wuhan-based enterprises and government departments engaged in face-to-face exchanges with British companies and institutions, covering a wide range of sectors including finance, trade, pharmaceuticals, education, telecommunications, and transportation.

On January 31, 2018, UK Prime Minister Theresa May arrived in Wuhan.

Many are curious about why Auntie Mei chose Wuhan as her first stop. Today, let’s explore the reasons behind this decision. The following data may offer some insights.

Wuhan Scenery

Currently, there are 310 foreign-invested enterprises established in Wuhan by the United Kingdom (including the British Virgin Islands, the Cayman Islands, etc.), with a total investment of USD 5.247 billion, contracted foreign capital of USD 3.406 billion, and actually utilized foreign capital of USD 3.406 billion. Wuhan boasts unique geographical advantages as part of the Belt and Road Initiative, the urban agglomeration in the middle reaches of the Yangtze River, and a major national transportation hub, along with a high-quality talent pool of one million university students. It has ranked among the top ten Chinese cities in GDP for six consecutive years. In addition to cooperation in the education sector, the UK side stated that it will focus on advancing collaboration with Wuhan in infrastructure development, smart city initiatives, the information industry, life sciences, and healthcare. Next, let us examine the cooperation in the medical field during Prime Minister May’s visit to China.

Theresa May Poses for a Photo with Chinese Entrepreneurs Including Jack Ma

AstraZeneca, a renowned innovative biopharmaceutical company in the UK, has signed strategic cooperation memoranda with two Chinese internet giants, Tencent and Ali Health, in Beijing and Shanghai respectively. Driven by new technologies such as the Internet, artificial intelligence, and the Internet of Things, the partnerships aim to create new models of smart health services and support the realization of the “Healthy China” initiative.

AstraZeneca Signs Agreement with AliHealth

AstraZeneca and Alibaba Health Jointly Announce Long-Term Strategic Partnership in “Smart Health,” Integrating AstraZeneca’s Patient-Centered, Integrated Innovative Diagnosis and Treatment Solutions with Alibaba Health’s Technical Expertise in Drug Traceability, E-Commerce, Health Management, and Artificial Intelligence (AI) to Deliver Safe, Convenient, and Effective One-Stop Healthcare Services, Enhance Access to Advanced Therapies, and Promote the Development of New Smart Health Models.

AstraZeneca Signs Agreement with Tencent

Under the Strategic Cooperation Memorandum, AstraZeneca and Tencent will leverage the globally leading technologies of the Tencent Security Joint Laboratory and its robust social application scenarios to jointly create an innovative, big data-driven model for combating counterfeit medicines. By employing new technologies, forming new alliances, and fostering new ecosystems, the partnership aims to fight against the manufacture and sale of counterfeit drugs, strengthen intellectual property protection, and fully safeguard public safety in medication use as well as legitimate rights and interests. This collaboration also sets a precedent in China as the first instance of an internet platform partnering with an international pharmaceutical company to combat counterfeit medicines.

Medopad and Tencent Reach Cooperation Agreement

UK health technology company Medopad has signed cooperation agreements worth over $141 million with Chinese enterprises, including Tencent. The deal was reached during UK Prime Minister Theresa May’s visit to China. In addition to Tencent, Medopad’s Chinese partners include China Resources, GlaxoSmithKline China, Peking University, Lenovo New Vision, Ping An Good Doctor, and United Family Healthcare. Medopad provides diagnostic analytics for physicians and helps them maintain remote contact with patients. Prior to this, Medopad had secured a total of $30 million in investment.

With Prime Minister May’s visit to Wuhan, it is believed that Wuhan will garner increasing attention from the international market, and cooperation between China and the UK in the field of smart healthcare will become even closer. The “2018 4th International Smart Healthcare Innovation Forum & eHealthcare Innovation Awards Ceremony,” which brings together the latest topics, most distinguished guests, and leading enterprises in the smart healthcare sector, will be grandly held in Wuhan on May 26–27, 2018.

Leveraging the brand strength of the 11th China Bio-Industry Conference and the 3rd “China Optics Valley” International Biomedical Health Industry Expo, as well as the promotional advantages of more than ten national-level societies and associations including the Chinese Society for Biotechnology, this conference will be themed “Cooperation and Innovation in the Era of Medical Consortiums.” The agenda will cover hot topics such as medical consortiums and tiered diagnosis and treatment, telemedicine and medical imaging, chronic disease management integrated with big data, and artificial intelligence. To strengthen Sino-British healthcare cooperation, the conference will also partner with the British Consulate-General in Wuhan to host a special Sino-British Healthcare Forum, inviting leading UK digital health and AI companies, as well as relevant healthcare and government institutions, to share innovative practices in UK primary care and explore future directions for Sino-British collaboration.

Distinguished Speakers Gather at EHIFA 2018

Professor Richard Armstrong from the UK’s National Health Service (NHS) will deliver presentations at both the plenary session and the UK-focused segment, sharing insights on the UK’s primary care system and population health management leveraging patient data. Furthermore, the UK enjoys a global reputation in artificial intelligence, boasting industry giants such as DeepMind as well as rising stars like Babylon and Medopad. As China vigorously develops its AI industry, deeper collaboration between the two sides is certainly to be expected.

Join leading enterprises such as United Imaging Healthcare, Yingda Technology, Shijian Technology, Kayi, Xianmai Quantum, and Shuxin Medical, along with authoritative experts, in retracing the steps of “Aunt Mei” to explore the reasons behind her choice of Wuhan. We are confident that this two-day conference journey, centered on “Wuhan + Healthcare,” will prove to be a truly rewarding experience!

For more information on the conference and experts, please visit the official forum website:http://www.ehealthcareforum.com/。

Registration Inquiry

Mr. Xiao 13917465409 danielxiao@healife.com

Ms. Jiang 13524610200 susiejiang@healife.com

Ms. Liu 15221229886 Jessieliu@healife.com

Consultation on Speeches

Ms. Che 17749741882 fionache@healife.com

Media Partnership

Ms. Zhang 15618511301 Joycezhang@healife.com